HRGN (Harvard Apparatus Regenerative Technology) Net Margin %: -708.41% (As of Mar. 2026)


HRGN Harvard Apparatus Regenerative Technology Inc HRGN
34 GF Score
Price $1.39
GF Value $5.34
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology Net Margin %?

Harvard Apparatus Regenerative Technology HRGN 34 Net Margin % is -708.41% as of Mar. 2026. GuruFocus rates HRGN with a GF Score™ of 34/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,952 Consumer Packaged Goods companies, Harvard Apparatus Regenerative Technology ranks worse than 98.77% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Harvard Apparatus Regenerative Technology's Net Income for the three months ended in Mar. 2026 was $-1.60 Mil. Harvard Apparatus Regenerative Technology's Revenue for the three months ended in Mar. 2026 was $0.23 Mil. Therefore, Harvard Apparatus Regenerative Technology's net margin for the quarter that ended in Mar. 2026 was -708.41%.

The historical rank and industry rank for Harvard Apparatus Regenerative Technology's Net Margin % or its related term are showing as below:

HRGN' s Net Margin % Range Over the Past 10 Years
Min: -14120.73   Med: -5241.31   Max: -769.61
Current: -769.61


HRGN's Net Margin % is ranked worse than
98.77% of 1952 companies
in the Consumer Packaged Goods industry
Industry Median: 3.495 vs HRGN: -769.61

Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Harvard Apparatus Regenerative Technology Net Margin % Related Terms


Harvard Apparatus Regenerative Technology Net Margin % Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology Net Margin % Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -8,684.47 -1,798.14 -975.71

Harvard Apparatus Regenerative Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,686.67 -575.08 -1,382.11 -770.32 -708.41

HRGN vs DTEAF, WYGC, BFNH: Net Margin % Comparison

For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology Net Margin % vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Net Margin % falls into.


HRGN
34GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Apparatus Regenerative Technology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Harvard Apparatus Regenerative Technology's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.869/0.704
=-975.71 %

Harvard Apparatus Regenerative Technology's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.601/0.226
=-708.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -708.41% mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Net Margin % of -708.41% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Harvard Apparatus Regenerative Technology and its competitors. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1928 out of 1952 companies in the Consumer Packaged Goods industry, placing it in the top 98.8%.
Is Harvard Apparatus Regenerative Technology's Net Margin % too high?
Harvard Apparatus Regenerative Technology's current Net Margin % is -708.41%. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #1928 out of 1952 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Net Margin % compare to DTEAF and WYGC?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1928 out of 1952 companies for Net Margin %. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median Net Margin % is 3.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Consumer Packaged Goods company?
The median Net Margin % among Consumer Packaged Goods companies is 3.50, based on 1,952 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Harvard Apparatus Regenerative Technology and its competitors. For the Consumer Packaged Goods industry, the median Net Margin % is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current Net Margin % is -708.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current Net Margin % is -708.41%. Harvard Apparatus Regenerative Technology's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Net Margin % is -708.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

  • Net Margin %: -708.41%
  • GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
  • GF Score™: 34/100 with 2 warning signs

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
34GF Score

Get the complete analysis for HRGN

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$5.34
GF Value